Navigation Links
Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
Date:12/10/2010

THOUSAND OAKS, Calif., Dec. 10, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced results from new analyses comparing XGEVA™ (denosumab), the first new treatment for advanced cancer patients with bone metastases in nearly a decade to prevent skeletal-related events, to Zometa® (zoledronic acid). These results underscore the efficacy profile of XGEVA in preventing skeletal-related events (SREs) in patients with bone metastases from advanced breast cancer, as well as explore XGEVA's impact on pain and quality of life outcomes, compared to Zometa. These new results were presented at the 33rd Annual San Antonio Breast Cancer Symposium.

XGEVA was approved on Nov. 18, 2010 by the U.S. Food and Drug Administration (FDA) after a priority review, a designation reserved for drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. XGEVA is indicated for the prevention of SREs in patients with bone metastases from solid tumors. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma.

New Extended Treatment Phase Data from Pivotal Phase 3 Study "136" Demonstrates Continued Superiority of XGEVA Compared to Zometa (Abstract Number: P6-14-01)San Antonio Sponsored Press Briefing, Dec. 10, 2010 at 12:30 p.m. CT

An additional four months of double-blinded treatment data from the pivotal Phase 3 "136" study was presented in a press briefing at SABCS today. The data showed that XGEVA was superior to Zometa in delaying the time to first on-study SRE by 18 percent and time to first-and-subsequent on-study event by 22 percent.  Further, the median time to first on-study SRE was five months longer for the patients at risk in the XGEVA group (32.4 months) versus the Zometa group (27.4 months) in patients with advanced breast cancer and bone metastases HR 0.82 (95 percent C
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Amgen to Present at Deutsche Banks 2010 BioFEST
2. Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
3. Amgen Foundation and Ashokas Changemakers Announce Finalists in Patients
4. Choices
5. Empowerment Competition
6. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
7. Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LAs Promise
8. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
9. Amgen Announces Webcast of 2010 Third Quarter Financial Results
10. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
11. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014  In today,s marketplace, launching multiple ... challenging - as is managing a portfolio of products ... it possible - or even preferable - to pool ... can you combine resources and activities, and what marketing ... These are just a few of the dilemmas facing ...
(Date:7/25/2014)... July 25, 2014  Depomed, Inc. (NASDAQ: ... quarter fiscal year 2014 financial results after the market ... a conference call beginning at 4:30 pm EDT, 1:30 pm PDT ... the call by dialing 877-317-6789 ( United States ... also be available via a live webcast on the ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- ScriptPro, ... TCGRx, of Powers Lake, Wisconsin ... in a distribution and co-marketing agreement allowing ScriptPro ... pharmacies throughout the United States ... pharmacy management and workflow systems to retail and ...
Breaking Medicine Technology:Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3
... Filing for Novavax,s ... Seasonal Influenza Vaccine Candidate, ROCKVILLE, Md., April 16 ... received positive results from an,immunogenicity study in ferrets inoculated with ... Novavax to,complete its planned investigational new drug ("IND") application to,support ...
... MATEO, Calif., April 16 Anthera Pharmaceuticals,Inc., ... announced today that after completing its review,of ... independent Data Safety,Monitoring Board (DSMB) has recommended ... the IMPACTS (Investigation of the Modulation of,Phospholipase ...
Cached Medicine Technology:Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate 2Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate 3DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 2
(Date:7/27/2014)... July 27, 2014 The inaugural ... demonstrate their passion for protecting our environment and getting ... the Southwest, will go on hiking or camping outings, ... show their support for permanently protecting our land, water ... the Latino community’s perspective on the environment like the ...
(Date:7/27/2014)... 27, 2014 The North American security ... at $1570 million in 2014, and it is expected ... of 4.64%. The report incorporates the factors that influence ... of growth rates and projected total expenditure. The report ... global markets. Apart from the general overview of the ...
(Date:7/27/2014)... 1-Butene is a colorless, combustible gas with ... can be manufactured either through the separation from crude ... Linear alpha olefin (alkene) 1-Butene is a versatile chemical ... important chemicals such as linear light density polyethylene (LLDP), ... 1-Butene market is extremely competitive. The market has several ...
(Date:7/27/2014)... 27, 2014 Although Cigarette ... restricted to two companies, heavy government regulation results ... analyst Spencer Little, “Demand for cigarettes has declined ... health concerns, frequent anti-smoking campaigns, increasing regulation and ... is estimated to fall at a compound annual ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 A consolidated ... ( http://www.lawreward.com/risperdal/ ) filings is proceeding in the Philadelphia ... scheduled in August to discuss claims involving the antipsychotic ... updated on the court’s website indicates that the meeting ... a.m. At this time, parties in the litigation will ...
Breaking Medicine News(10 mins):Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Risperdal Meeting Scheduled for August in Pennsylvania Litigation, Bernstein Liebhard LLP Reports 2Health News:Risperdal Meeting Scheduled for August in Pennsylvania Litigation, Bernstein Liebhard LLP Reports 3Health News:Risperdal Meeting Scheduled for August in Pennsylvania Litigation, Bernstein Liebhard LLP Reports 4
... **SAVE THE DATE** April 14-16, 2009 in ... www.worldhealthcarecongress.com WOBURN, Mass., Feb. 19 At ... top leaders and innovators who are driving the $2.4 ... Safeway, Carlson Companies and Kelly Services who are responsible ...
... Industry Veteran Will Lead Company in Development of ,Next ... 19 Valensa International has appointed Dr. Rudi E. ... company. The move to add CEO duties for Dr. ... Parry Nutraceuticals (Division of E.I.D. Parry (India) Ltd, Chennai, ...
... of ApoE4 gene in offspring makes a difference, study finds, ... parents had Alzheimer,s and who carry the so-called Alzheimer,s gene ... older, a new study has found. , This memory decline ... had Alzheimer,s but who do not carry the gene, ...
... VAR ) today announced that it has received ... to help doctors to improve,treatments and outcomes in many cancer ... radiation to control and manage tumors while,significantly reducing damage to ... "CE mark is an important milestone in Varian,s initiative to ...
... BOSTON, Feb. 19 Solos Endoscopy, Inc. (Pink ... Company,s breast endoscopy product line, the MammoView(TM), ... Surgical Products Magazine in the December 2008 issue. ... allow Physicians direct visualization, while examining lesions in ...
... SAN FRANCISCO, Calif., Feb. 19 Poniard Pharmaceuticals, Inc. ... on the development of innovative oncology products, today announced ... and senior vice president, effective February 18, 2009. Mr. ... operations of the Company. "Mr. Weaver has broad experience ...
Cached Medicine News:Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 2Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 3Health News:Valensa International's Dr. Rudi E. Moerck Appointed CEO 2Health News:If Parents Had Alzheimer's, Aging May Come Early 2Health News:If Parents Had Alzheimer's, Aging May Come Early 3Health News:Varian Medical Systems Has Received CE Mark for Proton Therapy System 2Health News:Solos Endoscopy, Inc.'s MammoView(TM) Featured in December Issue of Surgical Products Magazine 2Health News:Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer 2Health News:Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer 3
Capable of producing up to 500 volts and 500 milliamps, this power supply is ideal for PAGE, SDS-PAGE, DNA or RNA submarine gels as well as all types of small format transfer apparatus....
... IEF to DNA sequencing, Thermo Series 90 ... routine electrophoretic applications. These power supplies ... or constant power operating modes, with automatic ... power of the Series 90 power supplies, ...
... for horizontal and vertical gel electrophoresis applications. ... In this power supply model, output is ... constant voltage. Four sets of output terminals ... This power supply's light, compact and stackable ...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
Medicine Products: